Updates

Scapa - Talks with Tapex (Korea) may resume

July 2013

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Scapa has issued its best results since 2001. For the year to 31 March, sales went up 9% to Â£209m whilst both pretax profit and eps lifted by 34% to Â£12.7m and 5.6p, respectively. Net cash was Â£7.6m. The shining star was healthcare, which includes the Webtec acquisition, and where Scapa's focus is on four key market sectors (advanced wound care, medical device, consumer wellness and transdermal drug delivery). After assembling a strong team, finance director Paul Edwards says Scapa is moving up the value chain by supplying the end customer with products, which have been designed, manufactured, coated, packed and sterilised so all they have to do is sell it. This type of work is helping it to sign up multi-year agreements ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Digital Globe - Pays interim dividend in June

Alliance Pharma

Scapa - Factories "essential business" status (April 2020)

Scapa (December 2018)

Scapa (November 2017)

Scapa - Now a 10-bagger since 2011 (July 2017)

Scapa (November 2016)

Scapa - Debt down massively (May 2016)

Scapa (January 2016)

Scapa (November 2015)

Scapa (June 2015)

Scapa - Third profit upgrade since November (May 2015)

Scapa - £11.3m healthcare acquisition (April 2015)

Scapa - Moves to 24/7 shift working on healthcare side (July 2014)

Scapa - Healthcare side margins rocket (January 2014)

Scapa (December 2012)

Scapa (November 2012)

Scapa - Going to beat market forecasts (May 2012)

Scapa - Buys US adhesive-backed woundcare manufacturer (March 2012)

Scapa - New markets in medical and electronic tapes look good (November 2011)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X